New guidelines review strengths of current imaging modalities and make recommendations for using them to optimize patient management.
A new version of the Lifepak 15 monitor/defibrillator is designed to help hospital, as well as pre-hospital, teams provide more effective patient care. The 15, when used together with CODE-STAT data review software and the Lifenet system data network, empowers hospital and pre-hospital care teams with a powerful new suite of tools that utilize patient, performance and device data to improve care, trim operational costs and streamline equipment management.
May 3, 2011 – Being tall and obese may increase your risk for potentially dangerous blood clots, according to new research in Arteriosclerosis, Thrombosis and Vascular Biology: Journal of the American Heart Association.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
May 3, 2011 – European CE mark approval was granted and the first use announced for the Blazer open-irrigated radiofrequency (RF) ablation catheter. The Boston Scientific catheter is designed to treat a variety of arrhythmias such as atrial fibrillation, atrial flutter, ventricular tachycardia and other supraventricular tachycardias. The product is being launched this quarter in select CE mark countries.
Toshiba Medical Systems Corp. and advaced visualization software maker Vital Images Inc. announced they have entered into a definitive merger agreement.
May 2, 2011 – The mid-point for enrollment was reached in of the international APPOSITION III study of Stentys self-apposing coronary stent. About 250 patients are now enrolled out of a total of 500. The trial primary endpoint is major adverse cardiac events (MACE) at 12 months post-procedure.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Death rates are similar at one year for a catheter-based aortic valve replacement procedure and conventional surgery in ...
The RIVAL Trial, the largest randomized trial to compare radial access and femoral access for coronary angiography and ...
www.Womenheart.org‎ is the only national organization dedicated to promoting women's heart health through advocacy ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
April 26, 2011 – The U.S. Food and Drug Administration (FDA) announced this week it cleared Boston Scientific’s Ion paclitaxel-eluting coronary stent system. The stent, available for use with monorail or over-the-wire delivery systems, is made of platinum chromium (PtCr) alloy designed specifically for coronary stenting and intended to improve the acute performance of coronary stent implantation in the treatment of coronary artery disease. The stent’s alloy and design offer greater strength, enhanced deliverability and exceptional visibility. The thin-strut stent is designed for improved conformability, minimal recoil, and uniform lesion coverage and drug distribution
April 22, 2011 – The first patient has been treated in a European multicenter CIRCUS trial. The study is looking at NeuroVive Pharmaceutical’s CicloMulsion cremophor-free IV cyclosporine formulation in 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction.
April 22, 2011 – At the Society of Nuclear Medicine’s annual meeting, Philips will highlight several new imaging systems. The meeting will take place June 4-8 in San Antonio, Texas.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
April 22, 2011 – The American Diabetes Association (ADA) has invited NewCardio to present the results of a key study of the company’s urgent care solution, my3KG. Results showed that the solution had substantially greater accuracy than expert cardiologists' interpretation of standard 12-lead ECG (12L ECG) in diagnosing acute myocardial infarction (AMI) in diabetic patients.
April 22, 2011 – A new study found that coronary artery bypass surgery added to medical therapy for selected chronic heart failure patients offered benefits over medical therapy alone.
April 22, 2011 – The U.S. Food and Drug Administration (FDA) has cleared the Trifecta valve, by St. Jude Medical. The valve, a clinically-proven replacement for diseased, damaged or malfunctioning aortic heart valves, mimics the flow of a natural, healthy heart.